EDITORIAL Continued Progress in Therapy for Pulmonary Arterial Hypertension Darren B. Taichman, Jane A. Leopold, Greg Elliott N Engl J Med March 6, 2023DOI: 10.1056/NEJMe2300324 Pulmonary arterial hypertension is a devastating disorder characterized by precapillary pulmonary hypertension not caused by respiratory disease, obstruction of the pulmonary arteries, or certain less-common conditions. Idiopathic pulmonary arterial hypertension, heritable pulmonary ar...

ICU Management & Practice, Volume 22 - Issue 5, 2022 Improving Haemodynamic Management of ICU Patients: Decatecholaminisation & Cardiac Stress Reduction A summary of a symposium organised by AOP Health with presentations from Ricard Ferrer, Vall d’Hebron University Hospital, Barcelona, Spain; Bruno Levy, Centre Hospitalier Universitaire de Nancy, CHU Nancy · Réanimation Médicale Brabois, France; and Michael Fries, St. Vincenz Krankenhaus Limburg, Depart...

COMMENT|ONLINE FIRST Remdesivir saves lives. Were 3 years needed to learn that? Andre C Kalil Lancet Respir Med Published: February 21, 2023 DOI:https://doi.org/10.1016/S2213-2600(23)00036-X In The Lancet Respiratory Medicine, Alain Amstutz and colleagues1address a 3-year-old controversy: does remdesivir reduce mortality in patients hospitalised for COVID-19? Remdesivir is a viral RNA polymerase inhibitor that was evaluated in patients hospitalised for C...

Impact of Fatigue on Anaesthesia Providers Fatigue is being recognised as a workplace hazard of increasing concern. It is a significant problem for anaesthesiologists who have long working hours and irregular schedules. Fatigue negatively impacts vigilance, communication, and teamwork and shows decreased performance during psychomotor testing. However, its impact on real-life performance is uncertain. Fatigue is a complex issue with many definitions proposed in ...

COMMENT|ONLINE FIRST Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants Carlos K H Wong, Kristy T K Lau, Gabriel M Leung Lancet Infect Dis Published: February 10, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00056-7 Over the past year of the COVID-19 pandemic, populations worldwide have been facing the constant threat of the SARS-CoV-2 omicron variant and its sublineages, and the high transmissibility and ...

Shifting Sepsis Quality Measures From Processes to Outcomes Sepsis is a significant health issue that leads to high rates of death and disability, with over 250,000 adult deaths annually in the U.S. alone. Healthcare providers, patients, regulatory agencies, and advocates for quality improvement acknowledge the importance of preventing sepsis and improving its outcomes.  The Severe Sepsis/Septic Shock Early Management Bundle (SEP-1) from the Centers for Med...

COMMENT|ONLINE FIRST SARS-CoV-2 rebound with and without antivirals Nicola Petrosillo Lancet Infect Dis Published: February 13, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00063-4 As the COVID-19 pandemic continues, interventions for preventing SARS-CoV-2 transmission and progression to severe disease remain priorities. Vaccines against COVID-19 have an important role in preventing symptomatic infections that would otherwise lead to hospitalisation and d...

World Sepsis Day The Global Sepsis Alliance (GSA) and the Sepsis Stiftung joined together to celebrate 10 years of World Sepsis Day on 16 September 2022 in Berlin, under the theme of " Making Sepsis a National and Global Health Priority”. The event aimed to engage with high-level policy makers, representatives of health authorities, patient organizations, health care providers, science, industry, and civil society, to learn from each other through networking a...

New Paradigm of Personalised Sedation Lung-protective ventilation (LPV) limits lung injury (VILI). However, deep sedation is required to tolerate LPV, and patient self-induced lung injury (P-SILI) can occur during spontaneous breathing along with high respiratory efforts, lung stress and strain. Prevention of P-SILI may require further sedation. In addition, patient-ventilator dyssynchrony can worsen outcomes, resulting in increased sedation.  Ventilation t...

Editor's Note  February 20, 2023 At a Higher Dose and Longer Duration, Ivermectin Still Not Effective Against COVID-19 Kirsten Bibbins-Domingo, Preeti N. Malani JAMA. Published online February 20, 2023. doi:10.1001/jama.2023.1922 ACochrane meta-analysis of 11 eligible trials examining the efficacy of ivermectin for the treatment of COVID-19 published through April 2022 concluded that ivermectin has no beneficial effect for people with COVID-1...